NASDAQ:AEMD Aethlon Medical (AEMD) Stock Price, News & Analysis → A lot of people are making this costly mistake (From WealthPress) (Ad) Free AEMD Stock Alerts $1.68 -0.03 (-1.75%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$1.67▼$1.7450-Day Range$1.63▼$1.9952-Week Range$1.40▼$7.20Volume14,918 shsAverage Volume8,702 shsMarket Capitalization$4.40 millionP/E RatioN/ADividend YieldN/APrice Target$10.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Aethlon Medical alerts: Email Address Aethlon Medical MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside495.2% Upside$10.00 Price TargetShort InterestHealthy0.39% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.22Based on 5 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($4.98) to ($5.27) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.71 out of 5 stars 3.5 Analyst's Opinion Consensus RatingAethlon Medical has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $10.00, Aethlon Medical has a forecasted upside of 495.2% from its current price of $1.68.Amount of Analyst CoverageAethlon Medical has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.39% of the float of Aethlon Medical has been sold short.Short Interest Ratio / Days to CoverAethlon Medical has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Aethlon Medical has recently increased by 33.78%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAethlon Medical does not currently pay a dividend.Dividend GrowthAethlon Medical does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for AEMD. Previous Next 2.3 News and Social Media Coverage News SentimentAethlon Medical has a news sentiment score of 0.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Aethlon Medical this week, compared to 1 article on an average week.MarketBeat Follows3 people have added Aethlon Medical to their MarketBeat watchlist in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Aethlon Medical insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.00% of the stock of Aethlon Medical is held by insiders.Percentage Held by InstitutionsOnly 1.99% of the stock of Aethlon Medical is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Aethlon Medical are expected to decrease in the coming year, from ($4.98) to ($5.27) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aethlon Medical is -0.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aethlon Medical is -0.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAethlon Medical has a P/B Ratio of 0.26. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaSHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now. About Aethlon Medical Stock (NASDAQ:AEMD)Aethlon Medical, Inc., a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses from the human circulatory system. The company was founded in 1999 and is based in San Diego, California.Read More AEMD Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AEMD Stock News HeadlinesMarch 29, 2024 | americanbankingnews.comShort Interest in Aethlon Medical, Inc. (NASDAQ:AEMD) Expands By 33.8%March 27, 2024 | americanbankingnews.comAethlon Medical (NASDAQ:AEMD) Now Covered by StockNews.comMarch 29, 2024 | WealthPress (Ad)A lot of people are making this costly mistakeYou may have heard the saying “options are risky” … And, they can be. But only if you use them the way a lot of folks do. A lot of people think of BUYING speculative options when they talk about options. And BUYING low probability, speculative options is definitely risky… It’s how some folks leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. March 25, 2024 | money.usnews.comAethlon Medical IncMarch 19, 2024 | americanbankingnews.comAethlon Medical (NASDAQ:AEMD) Earns Sell Rating from Analysts at StockNews.comMarch 4, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Connect Biopharma Holdings (CNTB), Aethlon Medical (AEMD) and Aclaris Therapeutics (ACRS)March 2, 2024 | investing.comAethlon Medical Inc (AEMD)February 21, 2024 | finanznachrichten.deAethlon Medical, Inc.: Aethlon Medical Enters Into Materials Transfer Agreement for Santersus AG's NucleoCapture and HemoNucleoCapture DevicesMarch 29, 2024 | WealthPress (Ad)The ProTrader Dashboard is simple to use! (trade demo inside)Top traders like Kathy, Philip, Matt and Michael made out like bandits… “Took 65% profit on VFC today! Thanks!” - Kathy L. “Made 72% on VFC” - Philip “VFC was good, made $1,000 bucks” - Matt (estimated starting stake $1K) “VFC crushed it… Up 114% for a $3,249 profit!” - Michael It’s all thanks to the all-new ProTrader Dashboard… And today’s your chance to become one of the lucky ones to discover it for yourself.February 21, 2024 | markets.businessinsider.comAethlon Inks Materials Transfer Deal For Santersus' NucleoCapture And HemoNucleoCapture DevicesFebruary 21, 2024 | finance.yahoo.comAethlon Medical Enters Into Materials Transfer Agreement for Santersus AG's NucleoCapture and HemoNucleoCapture DevicesFebruary 21, 2024 | prnewswire.comAethlon Medical Enters Into Materials Transfer Agreement for Santersus AG's NucleoCapture and HemoNucleoCapture DevicesFebruary 18, 2024 | finanznachrichten.deAethlon Medical, Inc.: Aethlon Medical Announces Fiscal Third Quarter Financial Results and Provides Corporate UpdateFebruary 15, 2024 | finance.yahoo.comAEMD: Focus on Oncology Studies; In Vitro Binding Study Expected to Advance Clinical Trial ActivitiesFebruary 15, 2024 | finance.yahoo.comAethlon Medical, Inc. (NASDAQ:AEMD) Q3 2024 Earnings Call TranscriptFebruary 14, 2024 | finance.yahoo.comAethlon Medical Announces Fiscal Third Quarter Financial Results and Provides Corporate UpdateFebruary 14, 2024 | prnewswire.comAethlon Medical Announces Fiscal Third Quarter Financial Results and Provides Corporate UpdateFebruary 13, 2024 | msn.comAethlon Medical Q3 2024 Earnings PreviewFebruary 13, 2024 | benzinga.comEarnings Preview: Aethlon MedicalFebruary 7, 2024 | finance.yahoo.comAethlon Medical to Release Fiscal Third Quarter Financial Results and Host Conference Call on February 14, 2024November 18, 2023 | markets.businessinsider.comMaxim Group Keeps Their Hold Rating on Aethlon Medical (AEMD)November 16, 2023 | finance.yahoo.comAEMD: Expect Focus on Oncology Studies; Cost Containment EffortsNovember 16, 2023 | finance.yahoo.comAethlon Medical, Inc. (NASDAQ:AEMD) Q2 2024 Earnings Call TranscriptNovember 14, 2023 | finance.yahoo.comAethlon Medical Announces Fiscal Second Quarter Financial Results and Provides Corporate UpdateNovember 13, 2023 | benzinga.comA Preview Of Aethlon Medical's EarningsNovember 13, 2023 | finance.yahoo.comAethlon Medical Announces Appointment of James B. Frakes, M.B.A. as Interim Chief Executive Officer and Guy Cipriani, M.B.A. as Chief Operating OfficerNovember 11, 2023 | morningstar.comAethlon Medical Inc AEMDSee More Headlines Receive AEMD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aethlon Medical and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/14/2024Today3/29/2024Fiscal Year End3/31/2024Next Earnings (Estimated)6/26/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:AEMD CUSIPN/A CIK773910 Webwww.aethlonmedical.com Phone(858) 459-7800FaxN/AEmployees15Year FoundedN/APrice Target and Rating Average Stock Price Target$10.00 High Stock Price Target$10.00 Low Stock Price Target$10.00 Potential Upside/Downside+495.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($4.99) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-12,030,000.00 Net MarginsN/A Pretax Margin-2,133.97% Return on Equity-106.28% Return on Assets-86.60% Debt Debt-to-Equity RatioN/A Current Ratio3.93 Quick Ratio3.93 Sales & Book Value Annual Sales$570,000.00 Price / Sales7.72 Cash FlowN/A Price / Cash FlowN/A Book Value$6.56 per share Price / Book0.26Miscellaneous Outstanding Shares2,620,000Free Float2,515,000Market Cap$4.40 million OptionableOptionable Beta1.89 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. Guy F. Cipriani BS (Eng.) (Age 54)MBA, Chief Operating Officer Comp: $347.5kDr. Steven P. LaRosa M.D. (Age 57)Chief Medical Officer Comp: $430kMr. James B. Frakes M.B.A. (Age 67)Interim CEO, CFO, Secretary & Director Comp: $385kDr. Lee D. Arnold Ph.D. (Age 64)Chief Scientific Officer Key CompetitorsMinerva SurgicalNASDAQ:UTRSVenus ConceptNASDAQ:VEROSharps TechnologyNASDAQ:STSSTitan MedicalNASDAQ:TMDIFAcutus MedicalNASDAQ:AFIBView All CompetitorsInstitutional OwnershipVanguard Group Inc.Sold 169,433 shares on 3/11/2024Ownership: 0.810%Vanguard Group Inc.Sold 169,433 shares on 2/15/2024Ownership: 0.852%Simplex Trading LLCSold 100 shares on 2/2/2024Ownership: 0.000%View All Institutional Transactions AEMD Stock Analysis - Frequently Asked Questions Should I buy or sell Aethlon Medical stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Aethlon Medical in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" AEMD shares. View AEMD analyst ratings or view top-rated stocks. What is Aethlon Medical's stock price target for 2024? 1 Wall Street analysts have issued twelve-month price targets for Aethlon Medical's stock. Their AEMD share price targets range from $10.00 to $10.00. On average, they expect the company's share price to reach $10.00 in the next year. This suggests a possible upside of 495.2% from the stock's current price. View analysts price targets for AEMD or view top-rated stocks among Wall Street analysts. How have AEMD shares performed in 2024? Aethlon Medical's stock was trading at $2.19 on January 1st, 2024. Since then, AEMD shares have decreased by 23.3% and is now trading at $1.68. View the best growth stocks for 2024 here. Are investors shorting Aethlon Medical? Aethlon Medical saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 9,900 shares, an increase of 33.8% from the February 29th total of 7,400 shares. Based on an average daily volume of 11,900 shares, the days-to-cover ratio is presently 0.8 days. Approximately 0.4% of the shares of the stock are sold short. View Aethlon Medical's Short Interest. When is Aethlon Medical's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, June 26th 2024. View our AEMD earnings forecast. How were Aethlon Medical's earnings last quarter? Aethlon Medical, Inc. (NASDAQ:AEMD) issued its quarterly earnings results on Wednesday, February, 14th. The medical equipment provider reported ($1.37) earnings per share for the quarter, missing analysts' consensus estimates of ($1.23) by $0.14. When did Aethlon Medical's stock split? Shares of Aethlon Medical reverse split before market open on Thursday, October 5th 2023. The 1-10 reverse split was announced on Wednesday, October 4th 2023. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, October 4th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What other stocks do shareholders of Aethlon Medical own? Based on aggregate information from My MarketBeat watchlists, some companies that other Aethlon Medical investors own include Amarin (AMRN), Nokia Oyj (NOK), Vaxart (VXRT), VBI Vaccines (VBIV), Nabriva Therapeutics (NBRV), CRISPR Therapeutics (CRSP), Novavax (NVAX), Organigram (OGI), AT&T (T) and Who are Aethlon Medical's major shareholders? Aethlon Medical's stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (0.81%), Vanguard Group Inc. (0.85%), Concourse Financial Group Securities Inc. (0.00%) and Simplex Trading LLC (0.00%). View institutional ownership trends. How do I buy shares of Aethlon Medical? Shares of AEMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:AEMD) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders Alliance“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyFed launches fourth dollar overhaulStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aethlon Medical, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.